Develop, optimize and manufacture cell and gene therapies
Orgenesis and MIDA plan to deploy Orgenesis Mobile Processing Units and Labs (“OMPULs”) at leading hospitals for the onsite development of promising cell and gene therapies and immunotherapies from MIDA. The OMPULs are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities used to develop, optimize, and manufacture cell and gene therapies at the point of care. Via the collaboration with local partners, the teams will align with various hospitals with projects focused on scaling the therapies through to commercialization with regulatory compliance and governmental approval standards as guiding principles.
Orgenesis and MIDA entered into agreements to establish POCare centers and deploy OMPULs within leading hospitals in Italy, Germany, Spain and Benelux, as well as other activities including joint research, development and validation activities related to the development of cell and gene therapies.
Learn more about Orgenesis.